- Home
- MNKD vs ATRC Comparison
MNKD vs ATRC Comparison
Compare MNKD & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNKD
- ATRC
- Stock Information
- Founded
- MNKD 1991
- ATRC 2000
- Country
- MNKD United States
- ATRC United States
- Employees
- MNKD N/A
- ATRC N/A
- Industry
- MNKD Biotechnology: Pharmaceutical Preparations
- ATRC Medical/Dental Instruments
- Sector
- MNKD Health Care
- ATRC Health Care
- Exchange
- MNKD Nasdaq
- ATRC Nasdaq
- Market Cap
- MNKD 1.4B
- ATRC 1.5B
- IPO Year
- MNKD 2004
- ATRC 2005
- Fundamental
- Price
- MNKD $4.56
- ATRC $30.99
- Analyst Decision
- MNKD Buy
- ATRC Strong Buy
- Analyst Count
- MNKD 6
- ATRC 10
- Target Price
- MNKD $8.92
- ATRC $49.60
- AVG Volume (30 Days)
- MNKD 1.5M
- ATRC 735.3K
- Earning Date
- MNKD 05-08-2025
- ATRC 04-29-2025
- Dividend Yield
- MNKD N/A
- ATRC N/A
- EPS Growth
- MNKD 215.86
- ATRC N/A
- EPS
- MNKD 0.10
- ATRC N/A
- Revenue
- MNKD $297,595,000.00
- ATRC $480,076,000.00
- Revenue This Year
- MNKD $14.23
- ATRC $14.60
- Revenue Next Year
- MNKD $14.56
- ATRC $12.58
- P/E Ratio
- MNKD $46.04
- ATRC N/A
- Revenue Growth
- MNKD 32.50
- ATRC 15.79
- 52 Week Low
- MNKD $4.17
- ATRC $18.94
- 52 Week High
- MNKD $7.63
- ATRC $43.11
- Technical
- Relative Strength Index (RSI)
- MNKD 38.80
- ATRC 45.96
- Support Level
- MNKD $4.42
- ATRC $28.52
- Resistance Level
- MNKD $5.05
- ATRC $31.82
- Average True Range (ATR)
- MNKD 0.18
- ATRC 1.55
- MACD
- MNKD 0.00
- ATRC -0.01
- Stochastic Oscillator
- MNKD 20.59
- ATRC 36.94
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.